These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

949 related items for PubMed ID: 32697171

  • 1. Medication treatment for opioid use disorder and community pharmacy: Expanding care during a national epidemic and global pandemic.
    Cochran G, Bruneau J, Cox N, Gordon AJ.
    Subst Abus; 2020; 41(3):269-274. PubMed ID: 32697171
    [Abstract] [Full Text] [Related]

  • 2. Leveraging pharmacists to maintain and extend buprenorphine supply for opioid use disorder amid COVID-19 pandemic.
    Peckham AM, Ball J, Colvard MD, Dadiomov D, Hill LG, Nichols SD, Tallian K, Ventricelli DJ, Tran TH.
    Am J Health Syst Pharm; 2021 Mar 18; 78(7):613-618. PubMed ID: 33411894
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Stepped Care for Opioid Use Disorder Train the Trainer (SCOUTT) initiative: Expanding access to medication treatment for opioid use disorder within Veterans Health Administration facilities.
    Gordon AJ, Drexler K, Hawkins EJ, Burden J, Codell NK, Mhatre-Owens A, Dungan MT, Hagedorn H.
    Subst Abus; 2020 Mar 18; 41(3):275-282. PubMed ID: 32697170
    [Abstract] [Full Text] [Related]

  • 5. Massachusetts Justice Community Opioid Innovation Network (MassJCOIN).
    Evans EA, Stopka TJ, Pivovarova E, Murphy SM, Taxman FS, Ferguson WJ, Bernson D, Santelices C, McCollister KE, Hoskinson R, Lincoln T, Friedmann PD, MassJCOIN Research Group.
    J Subst Abuse Treat; 2021 Sep 18; 128():108275. PubMed ID: 33483222
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Medication treatment for opioid use disorder in the age of COVID-19: Can new regulations modify the opioid cascade?
    Nunes EV, Levin FR, Reilly MP, El-Bassel N.
    J Subst Abuse Treat; 2021 Mar 18; 122():108196. PubMed ID: 33221125
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Differences in the delivery of medications for opioid use disorder during hospitalization by racial categories: A retrospective cohort analysis.
    Priest KC, King CA, Englander H, Lovejoy TI, McCarty D.
    Subst Abus; 2022 Mar 18; 43(1):1251-1259. PubMed ID: 35670778
    [Abstract] [Full Text] [Related]

  • 15. Beliefs about medications for opioid use disorder among Florida criminal problem-solving court & dependency court staff.
    Andraka-Christou B, Atkins D.
    Am J Drug Alcohol Abuse; 2020 Nov 01; 46(6):749-760. PubMed ID: 32969757
    [Abstract] [Full Text] [Related]

  • 16. An ethical analysis of medication treatment for opioid use disorder (MOUD) for persons who are incarcerated.
    Brezel ER, Powell T, Fox AD.
    Subst Abus; 2020 Nov 01; 41(2):150-154. PubMed ID: 31800376
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 48.